Co-administration of pimavanserin with other agents
AssigneeACADIA Pharmaceuticals Inc.
InventorsUli HACKSELL, Krista MCFARLAND
Life of this patent
Estimating the term…
Abstract
As disclosed herein, co-administration of pimavanserin with an agent that ameliorates one or more cholinergic abnormalities can have a synergistic effect on the efficacy of the agent. Disclosed herein are compositions which include pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities. Also disclosed herein are methods for ameliorating or treating a disease condition characterized by one or more cholinergic abnormalities that can include administering pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities.
Claims20
1-32. (canceled)
A method for ameliorating or treating a disease condition characterized by one or more cholinergic abnormalities, comprising administering to a subject with the disease condition:
- (a) pimavanserin, or a pharmaceutically acceptable salt thereof;
- and
- (b) a cholinesterase inhibitor, wherein the cholinesterase inhibitor is metrifonate, physostigmine, neostigmine, pyridostigmine, demarcarium, rivastigmine, aldicarb, bendiocarb, bufencarb, carbaryl, carbendazim, carbetamide, carbofuran, chlorbufam, chloropropham, ethiofencarb, formetanate, methiocarb, methomyl, oxamyl, phenmedipham, pinmicarb, pirimcarb, propamocarb, propham, propoxus, donepezil, tacrine, edrophonium, echothiophate, diisopropyl fluorophosphate, dimebon, Huperzine A, ((2-[2-(1-benzylpiperidin-4-yl)ethyl]-2,3-dihydro-9-methoxy-1H-pyrrolo[3,4-b]quinolin-1-one hemifumarate)), zanapezil, phenserine, quilostigmine, ganstigmine, butyrophenones, imipramines, tropates, phencyclidines, curariforms, ethephon, ethopropazine, iso-OMPA, tetrahydrofurobenzofuran cymserine, N1-phenethyl-norcymserine, N8-benzylnorcymserine, N1,N8-bisnorcymserine, N1—N8-bisbenzylnorphysostigmine, N1,N8-bisbenzylnorphenserine, or N1,N8-bisbenzylnorcymserine.
Dependencies are inferred from the claim text.